Morgan Stanley Upgrades Dr. Reddy's Labs (RDY) to Overweight
RDY Hot Sheet
Rating Summary:1 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Morgan Stanley upgrades Dr. Reddy's Labs (NYSE: RDY) from Equalweight to Overweight.
Morgan analyst says, "...investors may be "underappreciating" the company's upcoming products for U.S. markets."
To see more analyst ratings on RDY Click Here.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company.
Morgan analyst says, "...investors may be "underappreciating" the company's upcoming products for U.S. markets."
To see more analyst ratings on RDY Click Here.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company.
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- Wells Fargo Upgrades Watson Pharmaceuticals (WPI) to Outperform; Actavis Acquisition Adds Growth Prospects
- TD Securities Upgrades Rogers Communications (RCI) to Buy; Negatives Priced In
Create E-mail Alert Related Categories
UpgradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
